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Abstract: Chronic inflammatory demyelinating polyneuropathy (CIDP) is the commonest 
chronic idiopathic dysimmune neuropathy. Pathophysiologic processes involve both cellular 
and humoral immunity. There are various known forms of CIDP, likely caused by varying 
mechanisms. CIDP in its different forms is a treatable disorder in the majority of patients. 
The diagnosis of CIDP is clinical, supported routinely by electrophysiology. Cerebrospinal 
fluid analysis may be helpful. Routine immunology currently rarely adds to the diagnostic 
process but may contribute to the identification of an associated monoclonal gammopathy 
with or without hematologic malignancy and the consideration of alternative diagnoses, such 
as POEMS syndrome, anti-myelin associated glycoprotein (MAG) neuropathy or chronic 
ataxic neuropathy, with ophthalmoplegia, M-protein, cold aglutinins and disialosyl antibodies 
(CANOMAD). The search for antibodies specific to CIDP has been unsuccessful for many 
years. Recently, antibodies to paranodal proteins have been identified in a minority of 
patients with severe CIDP phenotypes, often unresponsive to first-line therapies. In conjunc-
tion with reports of high rates of antibody responses to neural structures in CIDP, this 
entertains the hope that more discoveries are to come. Although still arguably for only 
a small minority of patients, in view of current knowledge, such progress will enable earlier 
accurate diagnosis with direct management implications but only if the important, unfortu-
nately and infrequently discussed issues of immunologic technique, test reliability and 
reproducibility are adequately tackled. 
Keywords: chronic inflammatory demyelinating polyneuropathy, dysimmune, immunologic, 
inflammatory, nodal, paranodal
Introduction
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare dysimmune 
peripheral nerve disorder of relatively recent description.1 It however represents the 
most common chronic immune-mediated neuropathy with a prevalence of about 
3 per 100,000 worldwide,2 but widely variable reported figures, likely due to 
different criteria used for case ascertainment.3 CIDP has a potential for effective 
treatment in the majority of affected individuals. The spectrum of the disorder has 
considerably expanded over the past few decades. In its classical form, also known 
as “typical CIDP”, patients present with symmetric weakness of proximal and distal 
muscles of the four limbs together with reduced sensation for proprioceptive 
modalities and absent or reduced reflexes.4 Several other CIDP subtypes have 
been described. These include focal, multifocal asymmetrical, distal, pure motor 
as well as pure sensory forms.4 A minority of subjects may present with cranial 
nerve involvement and an even smaller proportion, with respiratory muscle 
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weakness. CIDP, by current definitions, evolves over at 
least 8 weeks of continuous deterioration, with a relapsing 
or progressive course, as opposed to Guillain-Barré syn-
drome (GBS), which plateaus within 4 weeks. However, 
there are acute-onset forms of CIDP which in the early 
stages, may be difficult to separate from GBS. Despite 
similarities, CIDP otherwise differs from GBS as only 
seldom causes respiratory difficulties or facial weakness, 
while more commonly causing impairment of sensation, in 
particular, of proprioception.5 The diagnosis of CIDP 
relies on thorough history taking and neurological exam-
ination to ascertain the key features of the disorder. The 
main useful investigative procedure is electrophysiology, 
with in particular nerve conduction studies. These have the 
ability to establish electrical signs of demyelination of 
nerve fibers, by showing reduced conduction velocities 
along nerve segments, evaluating the presence of focal 
dysfunction of impulse transmission through conduction 
block and that of differential slowing in between fibers, 
through temporal dispersion.1 Due to the pathology affect-
ing proximal nerve roots, study of the cerebrospinal fluid 
(CSF) may be supportive of the diagnosis by revealing 
elevated protein content, although consideration of cut-offs 
used in relation to age and co-morbidities are essential as 
is awareness of poor specificity.6 Nerve imaging has been 
extensively studied in CIDP in recent years through mag-
netic resonance and ultrasonography (US). A number of 
issues, starting with their uncertain specificity versus CIDP 
mimics as well as their highly operator-dependent nature, 
however currently limit their utility in clinical practice, 
particularly with regard to MRI.7 Basic blood tests are 
done for incident cases of CIDP routinely and include 
blood count, electrolytes, renal and liver function, inflam-
matory markers, glycosylated haemoglobin (HbA1C) and 
HIV serology. Immunologic tests are frequently restricted 
to serum protein electrophoresis although immunofixation 
is preferable to identify low-level monoclonal proteins. 
Antibodies to anti-myelin associated glycoprotein (MAG) 
are commonly requested in presence of a monoclonal 
gammopathy of IgM subtype, but generally not done, 
otherwise.8 Search for antinuclear antibodies, antibodies 
to extractable nuclear antigens and antineuronal antibodies 
are done, especially when the clinical picture may suggest 
concurrent autoimmune disease or malignancy.9 Although 
not characteristically associated with CIDP, antiganglio-
side antibodies are often systematically requested in neu-
romuscular centers, less so in general neurologic practice. 
These immunologic tests, considered by many, as 
superfluous especially in typical presentations, may argu-
ably all lead to revising a diagnosis of CIDP, and more 
importantly still, have important consequences on further 
management and therapeutic decisions. For example, the 
presence of IgG anti-GM1 antibodies in a patient with 
GBS and successive re-deteriorations after treatment in 
the first 2 months makes the alternative and often consid-
ered diagnosis of acute-onset CIDP, most unlikely. 
Antibody positivity in this setting is clearly helpful in the 
diagnosis of GBS with “treatment-related fluctuations” vs 
that of CIDP, the latter, potentially leading to consideration 
of inappropriate and unnecessary but prolonged, treat-
ments. More recently, and in support of this view, the 
discovery of antibodies to paranodal proteins, albeit in 
a small proportion of individuals with CIDP, has resulted 
in considerable interest.10 The detection of these antibo-
dies described in presence of atypical phenotypes and 
treatment refractoriness to first-line agents has contributed 
to enhancing the immunologic interest of CIDP, from 
a new, clinically directly relevant, perspective and opening 
new avenues to the dysimmune aspect of CIDP as optimal 
diagnostic marker in the future.
We attempt in this review, to discuss in greater detail 
the immunologic aspects of CIDP and their potential cur-
rent, as well as future relevance within the clinical arena.
Pathophysiologic Aspects of CIDP
CIDP results from aberrant immune responses to periph-
eral nerve antigens. Synergy between cell-mediated and 
humoral immunity directed against antigens within periph-
eral nerve structures represents the likely underlying basis 
for the triggering of the pathophysiological processes.11 
These, in turn, lead to conduction dysfunction within the 
efferent and afferent components of the peripheral nervous 
system, with consequent motor and sensory impairments, 
ultimately resulting in neurologic disability. The evidence 
for a dysimmune process is supported by the efficacy of 
immune treatments and by the presence of features of 
inflammatory response in serum and nerve tissue of 
affected individuals.
Cellular immunity is implicated in CIDP pathogenesis 
as evidenced by inflammatory findings in peripheral 
nerves,12 as well as alterations of T-cell populations and 
functions,13 altered expression of cytokines and other 
inflammatory mediators.14 The breakdown of the blood 
nerve barrier to activated T cells allows their passage but 
also results in increased permeability of the barrier itself to 
pro-inflammatory factors. Inflammation represents the 
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pathological hallmark, characterized by edema and macro-
phagic infiltration of the endoneurium, perivascular aggre-
gation by T cells, increased cytokine expression and other 
inflammatory molecules. Demyelination of the peripheral 
nerve occurs through macrophagic and CD4+/CD8+ T cell 
presence.11 How the process is actually initiated remains 
uncertain.
Efficacy of plasma exchange and of intravenous immu-
noglobulins (IVIg) favors the implication of humoral 
mechanisms in CIDP, as does the presence of immunoglo-
bulin and complement in myelin structures of affected 
nerves.15 It is possible that molecular mimicry resulting 
from cross-reactivity to microbial antigens resembling 
neural components may be involved. Although demon-
strated in GBS through animal models,16 this has however 
not been established in CIDP, although the concept may be 
supported by the association of CIDP with malignancies 
such as melanomas,17 or infective or connective tissue 
disorders. Target antigens for specific antibodies in CIDP 
have remained however elusive despite extensive research 
in the field. Responses to various nerve antigens including 
myelin proteins P2, PMP22 and MPZ (P0) and glycolipids 
have been shown in small numbers of individuals with the 
disease, in few studies but not in others.10 However, and 
importantly, there have been several reports of 
a significant proportion of subjects with CIDP harboring 
antibodies to neural components.10 A number of case 
reports or small case series further illustrate this. For 
example, antiganglioside antibodies are described in multi-
focal motor neuropathy and GBS but have also been 
described, in albeit few patients with different CIDP sub-
types including anti-GM1,18 anti-GM2 and anti-GA1,19 
anti-LM1.20,21 Anti-GD1b antibodies of IgM subtype 
were described in a series of patients with ataxic CIDP, 
responsive to IVIg.22 Recently there have in addition, been 
reports of patients with anti-myelin associated glycopro-
tein (MAG) antibodies, with or without identifiable IgM 
monoclonal protein, presenting with a typical CIDP phe-
notype, instead of the supposedly usual phenotype asso-
ciated with “anti-MAG neuropathy” which is one of distal 
demyelinating sensory and motor (“DADS”: “distal 
acquired demyelinating sensory and motor”) 
neuropathy.23 In addition, the transition from DADS to 
typical CIDP may also occur in presence of anti-MAG 
positivity, which itself may pre-date the detection of an 
IgM monoclonal gammopathy.24 Importantly, it is note-
worthy that anti-MAG antibody testing methodology is 
in this regard, fundamental25 and that low titers may 
need considering with great caution.23 Also, additional 
other antibodies such as those directed against the 
Human Natural Killer1 epitope (anti-HNK1 antibodies), 
may be of use in diagnosing anti-MAG neuropathy, and 
be associated with disease severity.26
The most compelling findings in support of the 
renewed immunologic research interests in CIDP of poten-
tial for direct clinical application have appeared in the last 
decade.10,11 Nodal and paranodal structures have been 
discovered to harbor a number of antigens representing 
potential targets for immune attack in subjects with 
chronic dysimmune neuropathy. Ultrastructural disruption 
of the nodal/paranodal regions within the nerve sample of 
CIDP affected subjects was initially described nearly 10 
years ago.27 Since 2013, circulating antibodies to 
a number of antigenic structures within node and para-
node, have been identified.10 These are glycoproteins 
involved in maintaining cohesion between myelin and 
axonal structures in paranodal regions. Antibodies to 
these glycoproteins, namely neurofascin 155 (NF155),28 
contactin-1 (CNTN1),29 contactin-related protein 1 
(CASPR1),30 neurofascin 186 (NF186) and neurofascin 
140 (NF140)31 have been described although only in 
a minority of patients with CIDP, accounting for <10%,32 
or possibly even <5% of all cases, as per our own, recently 
published, experience.33 These antibodies have most fre-
quently been discovered in circumstances different to 
those expected in typical or classical CIDP, with acute or 
sub-acute disease onset and with particularly severe clin-
ical phenotypes as well as unresponsiveness to immuno-
globulin therapy.10
CIDP: Clinical Phenotypes and 
Immunology
The commonest form of CIDP, known as “typical CIDP”, 
presents with progressive onset over 8 weeks or more, of 
a symmetric polyradiculoneuropathy, involving proximal 
and distal limb regions, with weakness and large fiber 
sensory loss.4 Although motor deficits may be as marked 
proximally as they are distally, a length-dependent process 
is also present, likely due to secondary axonal loss, and may 
in practice result in predominant distal deficits by the time 
of presentation.34 Sensory deficits are similarly, frequently 
predominantly distal. In typical CIDP, immunologic studies 
may reveal the presence of a monoclonal gammopathy. 
When of IgG or IgA heavy chain, typical CIDP does not 
in the majority of cases differ from when the gammopathy 
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is absent, neither clinically, nor in treatment modalities or 
treatment response.8 Particular attention is essential for IgM 
gammopathies, although, in typical presentations, CIDP is 
in that case too, similarly managed. Exclusion of 
a hematologic malignancy by multidisciplinary neuro- 
hematologic collaboration and the necessary investigations 
is mandatory in all, so as to confirm a Monoclonal 
Gammopathy of Uncertain Significance (MGUS), which 
still require periodic surveillance.8 IgG/A gammopathies 
merit more concern when associated with a lambda 
rather than a kappa light chain. In such cases, presence of 
early distal axonal loss, atrophy and neuropathic pain 
may be suggestive of POEMS (Polyneuroneuropathy, 
Organomegaly, Endocrinopathy, M-protein, Skin) syn-
drome, which requires early diagnosis for appropriate treat-
ment without which outcome is very poor. Although the 
other non-neuropathic features are expected, the syndrome 
is often incomplete. Measurement of serum VEGF 
(Vascular Endothelial Growth Factor), bone marrow studies 
and skeletal X-rays are useful for diagnostic confirmation, 
the monoclonal gammopathy being itself most often of low 
level.35
Atypical forms of CIDP represent a substantial minor-
ity of all cases, as described in different cohorts.36 As 
demonstrated in large cohorts, such forms may also repre-
sent the initial phenotype which can however evolve over 
months to years to a typical CIDP, or, alternatively, remain 
unchanged.37 The most common atypical form of CIDP is 
the multifocal asymmetric presentation, also known as 
“Lewis Sumner syndrome” (“LSS”), or “MADSAM” 
(“multifocal asymmetrical demyelinating sensory and 
motor”) neuropathy. Patients with LSS present with asym-
metric deficits affecting two or more nerves. Upper limbs 
forms are more common.38 Various hypotheses have been 
formulated with regards to the pathophysiologic differ-
ences between LSS and typical CIDP. Cellular immunity 
was proposed as of importance in LSS as opposed to 
typical CIDP.39 This was based on electrophysiologic dif-
ferences of demyelinating patterns, with a predominance 
of intermediate segment involvement and multifocal con-
duction block in LSS, possibly due to disruption of the 
blood nerve barrier by local activation of cell-adhesion 
molecules, cytokines and other inflammatory mediators. 
In contrast, in typical CIDP, demyelination was found 
predominantly distal and hypothesized to be caused by 
predominant humoral mechanisms. It is possible proximal 
as well as distal, rather than intermediate nerve segments 
are predominantly affected in typical CIDP as represent 
areas of fragility of the blood nerve barrier. Differences in 
treatment response were also suggested as supporting this 
view, with good effect of steroids but not of IVIg in LSS.39 
However, this remains speculative, as other studies have 
found instead, poor response of LSS to steroids, or worse, 
deterioration with steroids, with, on the other hand, good 
response to IVIg.40 In addition, the presence of antigan-
glioside antibodies in a minority of patients described with 
LSS casts further uncertainty on precise pathophysiologic 
mechanisms involved.38 An overlap of LSS with multi-
focal motor neuropathy (MMN), which although a pure 
motor disorder may progressively involve sensory fibers, 
may be present. In presence of an MMN phenotype, sen-
sory involvement may be secondary to more diffuse axo-
nal loss and associated with disease severity, although 
remaining asymptomatic.41 Motor CIDP although rare is 
heterogeneous with pure weakness clinically, but in some 
cases, both motor and sensory electrophysiologic 
involvement.42 It presents with a symmetric picture affect-
ing the four limbs proximally and distally, differentiating it 
from multifocal motor neuropathy which is asymmetric 
and upper limb-predominant. However, IgM anti-GM1 
antibodies may occasionally be present in pure motor 
CIDP, as they are in about 50% of cases of MMN. Titers 
are similarly important and the relevance of low levels is 
uncertain. Avoidance of steroids is advised for motor 
CIDP as it is for MMN as there have been reports of 
deterioration, although it is possible that steroids may be 
safe and effective in the presence of sensory electrophy-
siologic abnormalities.37,42 Pure sensory CIDP presents 
mainly with sensory ataxia as a result of impaired 
proprioception.4 Motor function is preserved but this 
form of CIDP can be extremely disabling. The pure sen-
sory form can also consist of an asymptomatic motor 
component illustrated by slowed motor conduction velo-
cities. In addition, some patients have in addition to pre-
dominant sensory polyradiculopathy, some degree of 
sensory, postganglionic involvement.43 Alternatively, elec-
trophysiologic abnormalities may be exclusively sensory 
and there is also a rare form where no electrophysiologic 
defect is detected as a result of localized disease at the 
level of dorsal sensory rootlets. This form has become 
known as “chronic immune sensory polyradiculopathy” 
(“CISP”), and rare forms with concurrent motor root 
involvement have also recently been reported.44 CISP, or 
its variants, are not to date known to be associated with 
a specific antibody.
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Recently discovered anti-paranodal antibodies are 
associated with atypical CIDP phenotypes, expanding 
beyond the above-mentioned subtypes. The overwhelming 
majority of these antibodies are of IgG4 subtype, which 
are produced by regulatory B cells, and cannot fix com-
plement or bind to immunoglobulin receptors. IgG4 anti-
bodies, as a result, impair the function of their target 
antigens without involving inflammatory processes and, 
in the case of peripheral nerve disease, without causing 
demyelination.10 Patients with anti-NF155 antibodies have 
been described with predominant distal weakness, ataxia 
and atypical, invalidating low-frequency and high- 
amplitude tremor.28 Those with anti-CNTN1 antibodies 
have been reported with severe, predominantly motor dis-
ease of acute-onset30 with recent reports in addition to 
describing associated glomerulonephropathy.45 The few 
patients with anti-CASPR1 antibodies or antibodies to 
the CNTN1/CASPR1 complex have been described with 
acute GBS-like disease or with CIDP.10 The main common 
denominator in these patients was, in all reports, their poor 
response to conventional treatment, in particular intrave-
nous immunoglobulins. There have been several reports of 
the favorable effects of rituximab in this setting however,46 
as confirmed in our own experience, making prompt diag-
nosis offering a better chance of recovery, highly 
desirable.
Future Perspectives
The discovery of antibodies to paranodal proteins offers 
the prospect that the dysimmune nature of CIDP may in 
future be proven early and directly. This would, it may be 
argued, reduce reliance on other indirect investigations, 
principally electrophysiology, the sensitivity and specifi-
city of which, although appreciable, remains suboptimal.
However, it is apparent that only very few patients with 
a clinico-electrophysiological phenotype of CIDP are 
found to harbor these antibodies. It remains that previous 
studies considering other candidate antibodies have been 
in the setting of CIDP have been inconclusive. This leaves 
clinicians with little practical help from immunologic 
investigations at the current time, in diagnosis and man-
agement of subjects with clinically diagnosed, and electro-
physiologically confirmed (or not), CIDP. The issue of 
testing for other antibodies in the setting of CIDP is 
otherwise one of the differential diagnoses, to exclude 
anti-MAG activity, POEMS syndrome, disialosyl antibo-
dies in CANOMAD, Sjogren’s syndrome or SLE, or 
a paraneoplastic syndrome. This is clearly different from 
contributing directly to management within the CIDP 
spectrum itself.
It has been suggested that nearly half of patients with 
CIDP have antibodies against peripheral nerve myelin 
components. Although not contributing meaningfully to 
the management of the overwhelming majority of patients 
with CIDP to date, it may be hoped that this indicates the 
potential for future important advances in the field which 
may help tailor treatment to individual needs. In this 
regard, similar to antiparanodal antibodies appearing to 
suggest severe refractory disease, it is plausible other 
antibodies may similarly be discovered with other pheno-
types including in the substantial proportion of patients 
with milder, treatment-responsive as well as remitting dis-
ease. This would prove invaluable to optimize manage-
ment, reduce unnecessary and toxic therapies and their 
duration, as well as, importantly, provide optimistic prog-
nostication for patients and families early in the disease 
course. For this to become reality, however, the technical 
aspects of immunologic testing will be of paramount 
importance to ensure consistency, reliability and reprodu-
cibility in between laboratories. Yet another technically 
unreliable test is certainly not what is needed, given exist-
ing high misdiagnosis rates,47 however promising immu-
nology may appear for CIDP. Finally, it has to be kept in 
mind, that despite extensive research, it is perfectly defen-
sible to argue that antibodies identified so far, are clearly 
very rare and with little practical impact on patients’ 
management and thus, remain of academic interest.48 The 
modest progress made in the field despite decades of 
research provides little genuine hope for substantial 
major breakthrough findings in the near future. 
Improvement of patient care for dysimmune neuropathies 
may therefore not be as dependent on discoveries to come 
in neuroimmunology.
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